MannKind - Stock Price History | MNKD

Historical daily share price chart and data for MannKind since 2021 adjusted for splits. The latest closing stock price for MannKind as of September 23, 2021 is 4.75.
  • The all-time high MannKind stock closing price was 118.55 on September 23, 2004.
  • The MannKind 52-week high stock price is 6.25, which is 31.6% above the current share price.
  • The MannKind 52-week low stock price is 1.78, which is 62.5% below the current share price.
  • The average MannKind stock price for the last 52 weeks is 3.85.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
MannKind Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 1.7797 1.3000 4.0400 0.8415 3.1300 142.64%
2019 1.3499 1.1750 2.2500 1.0400 1.2900 21.70%
2018 1.9423 2.6600 3.8000 1.0100 1.0600 -54.31%
2017 2.2222 3.1570 6.7100 0.7052 2.3200 -27.12%
2016 4.7992 7.2500 10.8000 2.0860 3.1835 -56.09%
2015 22.1973 28.2000 37.9000 7.0500 7.2500 -72.20%
2014 34.0239 26.5500 54.8000 20.1000 26.0750 0.29%
2013 24.9329 11.9500 41.4500 11.7000 26.0000 125.11%
2012 11.4920 12.6000 17.0500 8.0000 11.5500 -7.60%
2011 19.0576 42.4500 49.1500 11.2500 12.5000 -68.98%
2010 35.4715 44.9500 53.9500 24.7000 40.3000 -7.99%
2009 30.7877 17.6500 59.0500 10.1000 43.8000 155.39%
2008 20.5350 39.3000 40.4625 10.1500 17.1500 -56.91%
2007 61.0176 80.8000 86.2000 37.9000 39.8000 -51.73%
2006 91.2221 56.2500 108.5000 56.2500 82.4500 46.45%
2005 62.1442 79.7500 79.7500 43.0000 56.3000 -28.51%
2004 80.9682 70.4000 118.5500 54.9000 78.7500 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.163B $0.065B
Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Company's lead product, the Technosphere Insulin System, consists of the Company's dry-powder Technosphere formulation of insulin and the Company's MedTone inhaler through which the powder is inhaled into the deep lung.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71